Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-07
2006-02-07
Andres, Janet (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S893000, C514S894000, C424S085400, C424S085700
Reexamination Certificate
active
06995133
ABSTRACT:
The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.
REFERENCES:
patent: 5914111 (1999-06-01), Wallner et al.
patent: 6007805 (1999-12-01), Foster et al.
patent: 6172046 (2001-01-01), Albrecht
Salmanian, A-H. et al., Synthesis and Expression of the gene for huamn epidermal growth factor in transgenic potato plants. (1996), Biotechnology Letters, vol. 18 No. 9, pp 1095-1098.
Davis, G.L. et al. “Treatment of Chronic Hepatitis C With Recombinant Interferon Alfa: A Multicenter Randomized, Controlled Trial”New England Journal of Medicinevol. 321, No. 22 (1989) pp 1501-1506.
Di Bisceglie, A.M. et al. “Recombinant Interferon Alfa Therapy for Chronic Hepatitis C: A Randomized, Double-Blind, . . . trial”New England Journal of Medicinevol. 321, No. 22 (1989) pp 1506-1510.
Soriano, V. et al. “Efficacy and Safety of α-Interferon Treatment for Chronic Hepatitis C in HIV-infected Patients”Journal of Infectionvol. 31, (1995) pp. 9-13.
Mauss, S. et al. “Response to Treatment of Chronic Hepatitis C with Interferon α in Patients Infected with HIV-1 Is Associated with Higher CD4+ Cell Count”Infectionvol. 26, No. 1 (1998) pp. 16-19.
Soriano, V. et al. “Interferon α for the Treatment of Chronic Hepatitis c in Patients Infected with Human Immunodeficiency Virus”Clinical Infectious Diseasesvol. 23 (1996) pp. 585-591.
Aguet, M. et al. “Various Human Interferon α Subclasses Cross-React with Common Receptors: Their Binding Affinities Correlate with Their Specific . . . Activities” Virology, vol. 132, p. 211-216, (1984).
Au, W.C. et al. “Virus-Mediated Induction of Interferon A Gene Requires Cooperation Between Multiple Binding Factors . . . Region” Journal of Biological Chemistry, vol. 268, No. 32, p. 24032-24040, (1993).
Bisat, F. et al. “Differential and Cell Type Specific Expression of Murine Alpha-Interferon Genes is Regulated on the Transcriptional Level” Nucleic Acids Research , vol. 16, No. 13, p. 6067-6083, (1988).
Brandt, E.R. et al. “Expression of IFN A Genes in Subpopulations of Peripheral Blood Cells” British Journal of Haematology, vol. 86, p. 717-725, (1994).
Chomczynski, P. et al. “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction” Analytical Biochemistry, vol. 162, p. 156-159, (1987).
Derynck, R. et al. “Isolation and Structure of a Human Fibroblast Interferon Gene” Nature, vol. 285, p. 542-547, (1997).
Fattovich, G. et al. “Morbidity and Mortality in Compensated Cirrhosis Type C: A Retrospective Follow-up . . . Patients” Gastroenterology, vol. 112, p. 463-472, (1997).
Foster, G.R. et al. “Differential Relative Activities of Human Cell-Derived Interferon-α Subtypes: IFN-α8 Has Very . . . Potency” Journal of Interferon and Cytokine Research, vol. 16, p. 1027-1033, (1996).
Geldelman, H.E. et al. “A Selective Defect of Interferon α Production in Human Immunodeficiency Virus-Infected Monocytes” Journal of Experimental Medicine, vol. 172, p. 1433-1442, (1990).
Gil, B. et al. “Hepatic and Extrahepatic HCV RNA Strands in Chronic Hepatitis C: Different Patterns of Response to Interferon Treatment” Hepatology, vol. 18, p. 1050-1054, (1993).
Goeddel, D.V. et al. “The Structure of Eight Distinct Cloned Human Leukocyte Interferon cDNAs” Nature, vol. 290, p. 20-26, (1981).
Hiscott, J. et al. “Differential Expression of Human Interferon Genes” Nucleic Acids Research, vol. 12, No. 9, (1984).
Knodell, R.G. et al. “Formulation and Application of a Numerical Scoring System for Assessing Histological Activity in Asymptomatic . . . Hepatitis” Hepatology, vol. 1, No. 5, p. 431-435, (1981).
Larrea, E. et al. “Tumor Necrosis Factor α Gene Expression and the Response to Interferon in Chronic Hepatitis C” Hepatology, vol. 23, p. 210-217, (1996).
Lopez, S. et al. “Silencer Activity in the Interferon-A Gene Promoters” Journal of Biological Chemistry, vol. 272, No. 36, p. 22788-22799, (1997).
De Maeyer, E. et al. “Interferons” The Cytokine Handbook, Chapter 11, p. 215-239, (1991).
Ng, S.Y. et al. “Evolution of the Functional Human β-Actin Gene and Its Multi-Pseudogene Family: Conservation . . . Pseudogenes” Molecular and Cellular Biology, vol. 5, No. 10, p. 2720-2732, (1985).
Poynard, T. et al. “Natural History of Liver Fibrosis Progression in Patients with Chronic Hepatitis C” The Lancet, vol. 349, p. 825-832, (1997).
Samuel, C.E. “Antiviral Actions of Interferon Interferon-Regulated Cellular Proteins and Their Surprisingly Selective Antiviral Activities” Virology, vol. 183, p. 1-11, (1991).
Sarobe, P. et al. “Production of Interleukin-2 in Response to Synthetic Peptides from Hepatitis C Virus E1 Protein in Patients . . . Treatment” Journal of Hepatology, vol. 25, p. 1-9, (1996).
Tilg, H. “New Insights Into the Mechanisms of Interferon Alfa: An Immunoregulatory and Anti-inflammatory Cytokine” Gastroenterology, V. 112, p. 1017-1021, (1997).
Tovey, M.G. et al. “Interferon Messenger RNA is Produced Constitutively in the Organs of Normal Individuals” Proc. Natl. Acad. Sci., vol. 84, p. 5038-5042, (1987).
Viazov, S. et al. “Typing of Hepatitis C Virus Isolates by DNA Enzyme Immunoassay” Journal of Virological Methods, vol. 48, p. 81-92, (1994).
Weissmann, C. et al. “The Interferon Genes” Progress in Nucleic Acid Research and Molecular Biology, vol. 33, p. 251-300, (1986).
Civeira Murillo Ma Pilar
Larrea Leoz Esther
Prieto Valtueña Jesús
Andres Janet
Ladas & Parry LLP
Proyecto de Biomedicina Cima, S.L.
Seharaseyon Jegatheesan
LandOfFree
Utilization of interferon alpha 5 in the treatment of viral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Utilization of interferon alpha 5 in the treatment of viral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Utilization of interferon alpha 5 in the treatment of viral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634004